6
Clinical Trials associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute) / Unknown statusPhase 1/2IIT Multi-center Phase I/II Clinical Trial of 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple 4SCAR-T cell therapy which targets GD2, PSMA and CD276 surface antigens in patients with relapsed and refractory neuroblastoma (NB). Another goal of the study is to understand the function of the multi-CAR-T cells and their persistency in the patients.
/ Unknown statusPhase 1/2IIT Primary, Booster and Consolidation Multi-CAR-T Cell Therapy for the Treatment of Refractory B Cell Lymphomas
This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) and BCL involving central nervous system (CNS-BCL). Clinical response and development of a simplified and standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Phase I/II Clinical Trial of 4SCAR-PSMA T Cell Therapy Targeting PSMA Positive Malignancies
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.
100 Clinical Results associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)
100 Translational Medicine associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)
100 Patents (Medical) associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)
100 Deals associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)